CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα

Swaathi Jayaraman, Michele Doucet, Wen Min Lau, Scott L. Kominsky

Research output: Research - peer-reviewArticle

Abstract

Previously, we identified the transcriptional coactivator CITED2 as a potential facilitator of bone metastasis using a murine mammary cancer model. Extending these studies to human breast cancer, it was observed that CITED2 mRNA expression was significantly elevated in patient specimens of metastatic breast cancer relative to primary tumors, with highest levels in metastasis to bone relative to non-bone sites. To further evaluate CITED2 functions in breast cancer metastasis, CITED2 expression was stably reduced in the human breast cancer cell lines MDA-MB-231 and MDA-MB-468, which are metastatic in animal models. While CITED2 knockdown had no effect on cell proliferation, cell migration and invasion were significantly reduced, as was the establishment of metastasis following intracardiac administration in athymic nude mice. To explore the mechanism behind these effects, gene expression following CITED2 knockdown in MDA-MB-231 cells by cDNA microarray was performed. As confirmed at the mRNA and protein levels in both MDA-MB-231 and MDA-MB-468 cells, expression of the NF-κB regulator IKKα was significantly reduced, along with several NF-κB targets with known roles in metastasis (OPN, MMP9, uPA, SPARC, IL11, and IL1β). Furthermore, ChIP assay revealed recruitment of CITED2 to the promoter of IKKα, indicating a direct role in regulating its expression. Consistent with reduced IKKα expression, CITED2 knockdown inhibited both canonical and noncanonical NF-κB signaling. Finally, restoration of IKKα expression following CITED2 knockdown in MDA-MB-231 and MDA-MB-468 cells rescued their invasive ability. Collectively, these data demonstrate that CITED2 modulates metastatic ability in human breast cancer cells, at least in part, through the regulation of IKKα. Implications: The current study highlights the role of CITED2 in facilitating breast cancer metastasis, partly via regulation of IKKα.

LanguageEnglish (US)
Pages730-739
Number of pages10
JournalMolecular Cancer Research
Volume14
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Nude Mice
Bone and Bones
Messenger RNA
Interleukin-11
Oligonucleotide Array Sequence Analysis
Cell Movement
Animal Models
Cell Proliferation
Gene Expression
Cell Line
Neoplasms
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα. / Jayaraman, Swaathi; Doucet, Michele; Lau, Wen Min; Kominsky, Scott L.

In: Molecular Cancer Research, Vol. 14, No. 8, 01.08.2016, p. 730-739.

Research output: Research - peer-reviewArticle

Jayaraman, Swaathi ; Doucet, Michele ; Lau, Wen Min ; Kominsky, Scott L./ CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα. In: Molecular Cancer Research. 2016 ; Vol. 14, No. 8. pp. 730-739
@article{928cf998a7a54cdbb2231639fd28cca1,
title = "CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα",
abstract = "Previously, we identified the transcriptional coactivator CITED2 as a potential facilitator of bone metastasis using a murine mammary cancer model. Extending these studies to human breast cancer, it was observed that CITED2 mRNA expression was significantly elevated in patient specimens of metastatic breast cancer relative to primary tumors, with highest levels in metastasis to bone relative to non-bone sites. To further evaluate CITED2 functions in breast cancer metastasis, CITED2 expression was stably reduced in the human breast cancer cell lines MDA-MB-231 and MDA-MB-468, which are metastatic in animal models. While CITED2 knockdown had no effect on cell proliferation, cell migration and invasion were significantly reduced, as was the establishment of metastasis following intracardiac administration in athymic nude mice. To explore the mechanism behind these effects, gene expression following CITED2 knockdown in MDA-MB-231 cells by cDNA microarray was performed. As confirmed at the mRNA and protein levels in both MDA-MB-231 and MDA-MB-468 cells, expression of the NF-κB regulator IKKα was significantly reduced, along with several NF-κB targets with known roles in metastasis (OPN, MMP9, uPA, SPARC, IL11, and IL1β). Furthermore, ChIP assay revealed recruitment of CITED2 to the promoter of IKKα, indicating a direct role in regulating its expression. Consistent with reduced IKKα expression, CITED2 knockdown inhibited both canonical and noncanonical NF-κB signaling. Finally, restoration of IKKα expression following CITED2 knockdown in MDA-MB-231 and MDA-MB-468 cells rescued their invasive ability. Collectively, these data demonstrate that CITED2 modulates metastatic ability in human breast cancer cells, at least in part, through the regulation of IKKα. Implications: The current study highlights the role of CITED2 in facilitating breast cancer metastasis, partly via regulation of IKKα.",
author = "Swaathi Jayaraman and Michele Doucet and Lau, {Wen Min} and Kominsky, {Scott L.}",
year = "2016",
month = "8",
doi = "10.1158/1541-7786.MCR-16-0081",
volume = "14",
pages = "730--739",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα

AU - Jayaraman,Swaathi

AU - Doucet,Michele

AU - Lau,Wen Min

AU - Kominsky,Scott L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Previously, we identified the transcriptional coactivator CITED2 as a potential facilitator of bone metastasis using a murine mammary cancer model. Extending these studies to human breast cancer, it was observed that CITED2 mRNA expression was significantly elevated in patient specimens of metastatic breast cancer relative to primary tumors, with highest levels in metastasis to bone relative to non-bone sites. To further evaluate CITED2 functions in breast cancer metastasis, CITED2 expression was stably reduced in the human breast cancer cell lines MDA-MB-231 and MDA-MB-468, which are metastatic in animal models. While CITED2 knockdown had no effect on cell proliferation, cell migration and invasion were significantly reduced, as was the establishment of metastasis following intracardiac administration in athymic nude mice. To explore the mechanism behind these effects, gene expression following CITED2 knockdown in MDA-MB-231 cells by cDNA microarray was performed. As confirmed at the mRNA and protein levels in both MDA-MB-231 and MDA-MB-468 cells, expression of the NF-κB regulator IKKα was significantly reduced, along with several NF-κB targets with known roles in metastasis (OPN, MMP9, uPA, SPARC, IL11, and IL1β). Furthermore, ChIP assay revealed recruitment of CITED2 to the promoter of IKKα, indicating a direct role in regulating its expression. Consistent with reduced IKKα expression, CITED2 knockdown inhibited both canonical and noncanonical NF-κB signaling. Finally, restoration of IKKα expression following CITED2 knockdown in MDA-MB-231 and MDA-MB-468 cells rescued their invasive ability. Collectively, these data demonstrate that CITED2 modulates metastatic ability in human breast cancer cells, at least in part, through the regulation of IKKα. Implications: The current study highlights the role of CITED2 in facilitating breast cancer metastasis, partly via regulation of IKKα.

AB - Previously, we identified the transcriptional coactivator CITED2 as a potential facilitator of bone metastasis using a murine mammary cancer model. Extending these studies to human breast cancer, it was observed that CITED2 mRNA expression was significantly elevated in patient specimens of metastatic breast cancer relative to primary tumors, with highest levels in metastasis to bone relative to non-bone sites. To further evaluate CITED2 functions in breast cancer metastasis, CITED2 expression was stably reduced in the human breast cancer cell lines MDA-MB-231 and MDA-MB-468, which are metastatic in animal models. While CITED2 knockdown had no effect on cell proliferation, cell migration and invasion were significantly reduced, as was the establishment of metastasis following intracardiac administration in athymic nude mice. To explore the mechanism behind these effects, gene expression following CITED2 knockdown in MDA-MB-231 cells by cDNA microarray was performed. As confirmed at the mRNA and protein levels in both MDA-MB-231 and MDA-MB-468 cells, expression of the NF-κB regulator IKKα was significantly reduced, along with several NF-κB targets with known roles in metastasis (OPN, MMP9, uPA, SPARC, IL11, and IL1β). Furthermore, ChIP assay revealed recruitment of CITED2 to the promoter of IKKα, indicating a direct role in regulating its expression. Consistent with reduced IKKα expression, CITED2 knockdown inhibited both canonical and noncanonical NF-κB signaling. Finally, restoration of IKKα expression following CITED2 knockdown in MDA-MB-231 and MDA-MB-468 cells rescued their invasive ability. Collectively, these data demonstrate that CITED2 modulates metastatic ability in human breast cancer cells, at least in part, through the regulation of IKKα. Implications: The current study highlights the role of CITED2 in facilitating breast cancer metastasis, partly via regulation of IKKα.

UR - http://www.scopus.com/inward/record.url?scp=84982161954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982161954&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-16-0081

DO - 10.1158/1541-7786.MCR-16-0081

M3 - Article

VL - 14

SP - 730

EP - 739

JO - Molecular Cancer Research

T2 - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 8

ER -